Psychology & Behavioral Science Active Updated Oct 6, 2026
Psilocybin's move into the clinic
Where it stands as of Sep 22, 2026
Psilocybin trials are multiplying and industry is buying in, with Eli Lilly agreeing to acquire the psychedelics biotech AtaiBeckley and Compass Pathways' COMP360 now meeting its primary endpoint in a second Phase 3 depression trial. A separate Oxford trial of 59 depressed patients found both psilocybin and the SSRI escitalopram reduced the brain's negative interpretation bias, the first evidence the two treatments may relieve depression through a shared mechanism despite psilocybin's faster onset. What still is no
Once taboo, psilocybin is being tested as a fast-acting treatment for depression and suicidal thoughts, with early and surprising signals in advanced dementia.
Oct 6, 2026 Latest
PsyPost reported a small study of 20 people given a high psilocybin dose for alcohol use disorder. The 11 still abstinent at three months had talked more about inner dialogue and changing habits the day after, while those who drank again talked more about sensations and visions.
Oct 4, 2026
PsyPost reported that 20 people with post-treatment Lyme disease had 40 percent lower symptom burden six months after two supported psilocybin sessions, in a study with no control group.
Sep 25, 2026
Researchers at Nanyang Technological University Singapore and Hong Kong Baptist University gave a single dose of psilocybin to mice bred without the Cntnap2 autism-linked gene and found lasting increases in social behavior, with the same durable effect seen even when the mice were anesthetized through the drug's acute phase.
Sep 22, 2026
Compass Pathways' psilocybin therapy COMP360 met its primary endpoint in a second Phase 3 depression trial.
Sep 21, 2026
A double-blind Oxford trial led by Marieke Martens and Robin Carhart-Harris gave 59 depressed patients either two doses of psilocybin three weeks apart or six weeks of daily escitalopram and found both treatments reduced the brain's tendency to read neutral or ambiguous faces and comments as hostile.
Sep 11, 2026
A mouse study published in Science found that giving psilocybin before chemotherapy kept mitochondria moving and functioning inside nerve axons, preventing chemotherapy-induced peripheral neuropathy entirely, with MD Anderson researchers led by Moran Amit and pain researcher Patrick Dougherty connecting chemo's mitochondrial nerve damage to the psychedelic's nerve-protective effect through the serotonin 2A receptor.
Aug 30, 2026
In a small Johns Hopkins pilot trial, two supervised doses of psilocybin cut chronic post-treatment Lyme disease symptoms roughly in half, with depression, sleep trouble and pain still meaningfully improved six months later.
Aug 20, 2026
A five-year Monash University study, the largest single-site psychedelic neuroimaging dataset yet, scanned 62 psychedelic-naive adults with EEG and fMRI before and after psilocybin and found individual brain activity reorganized into patterns tied to each person's actual activity and experience rather than simply dissolving into chaos, led by senior author Adeel Razi.
Aug 17, 2026
University of Pennsylvania researchers Joseph Cichon, Ahmad Hammo and Stephen Wisser gave mice with chronic pain a single injection of psilocybin targeting the anterior cingulate cortex, the shared brain circuit for emotion and pain unpleasantness, and by the next day both pain sensitivity and depression-like withdrawal had reversed, with the effect lasting at least twelve days, the full length of the study.
Aug 3, 2026
In the first US clinical trial of psilocybin-assisted therapy for treatment-resistant PTSD in military veterans, an 11-week Ohio State University protocol pairing therapy with two psilocybin doses produced remission in 9 of 12 participants one month after treatment with no serious adverse events. A separate UCSF study of 25 healthy adults used brain scans to show a single high dose shifts frontal-lobe circuits toward more flexible processing for a full month afterward, helping explain why the effect outlasts the drug.
Aug 2, 2026
A study using the 2024 National Survey Investigating Hallucinogenic Trends, led by Anita Cservenka of Oregon State University, found adults who used psilocybin alongside alcohol reported fewer depressive symptoms than adults who drank but did not use psilocybin, though the observational design cannot establish that psilocybin caused the difference.
Jul 31, 2026
A Stanford team led by postdoctoral scholar Adam Pines and senior author Leanne Williams applied an optical-flow technique borrowed from computer vision to brain scans from four independent studies of LSD, psilocybin and MDMA, and found all three drugs reliably reduce the flow of sensory signals rising into the default mode network, the brain region tied to self-reflection and rumination that runs abnormally in depression and schizophrenia.
Jul 22, 2026
A study led by Robin Carhart-Harris at UC San Francisco and Imperial College London gave 28 healthy adults a single dose of psilocybin and found that the size of the brain entropy spike during the trip predicted both next-day emotional insight and improved well-being a month later, suggesting the psychedelic experience itself, not just the drug in the bloodstream, drives the therapeutic effect.
Jul 17, 2026
Eli Lilly announced it would acquire AtaiBeckley, a psychedelics-focused biotech, marking a major pharmaceutical company's move into the psilocybin treatment space.
Jul 8, 2026
An FDA Phase 2 study across 35 sites and 84 participants found luvesilocin, a compound designed to work like psilocybin's active ingredient, showed rapid improvement in postpartum depression symptoms. The compound is designed to bring psilocybin's potential specifically to the hormonal and neurological context of the postpartum period, where nearly 20 percent of new mothers experience anxiety or depression.
Jun 27, 2026
A report described psilocybin temporarily restoring speech and mobility in a case of advanced Alzheimer's.
Jun 17, 2026
USC launched a clinical trial pairing psilocybin with mindfulness meditation, and a case described a woman in her eighties with advanced Alzheimer's briefly recovering speech after a dose.
Jun 14, 2026
A study reported that a single dose of psilocybin gave months of relief from chronic suicidal thoughts.
The checkable promises in this story, dated the day they were made. A promise is marked kept, slipped or partly met only when a later report says so; past its own date with no report, it reads "no word", which is what silence honestly is.
Luvesilocin, a psilocybin-like compound, showed rapid improvement in postpartum depression in an FDA Phase 2 study of 84 participants across 35 sites; whether Phase 3 trials confirm the effect size and safety specifically in postpartum patients is the open question.
Reporting in the Today Got Better brief
showed rapid improvement in postpartum depression symptoms in an FDA Phase 2 study across 35 sites and 84 participants
When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.
Free forever, no spam. One click to unsubscribe, and we never sell your email.